These data indicate that deletion of RIPK3 does not preclude imatinib from limiting the pathology associated with granulomatous lesions; moreover, the capacity of imatinib to limit pathology of granulomatous lesions resulting from Mm infection was abrogated in mice lacking CASP8. Here, CASP8 is linked to Miyoshi myopathy.